论文部分内容阅读
目的:探讨血浆uPA、uPAR在不同分子亚型乳腺癌中的表达水平及其对乳腺癌患者治疗、预后等的临床意义。方法:采用免疫组化ELISA方法测定的女性乳腺癌初治患者86例的血浆uPA、uPAR水平,所有患者均经组织病理学确诊,以患者的临床病理学资料提供的免疫组化结果为基础进行分子分型,结合二者进行分析。结果:血浆uPA在乳腺癌不同分子亚型中表达有统计学差异(P<0.01),uPAR在乳腺癌不同分子亚型中表达有统计学差异(P<0.05);乳腺癌患者血浆uPA和uPAR呈显著正相关(P<0.01,Pearson相关系数r=0.735)。结论:乳腺癌患者血浆uPA和uPAR的水平与分子亚型密切相关,他们和分子亚型联合,可能对乳腺癌个体化治疗及判定预后有指导意义。
Objective: To investigate the expression of plasma uPA and uPAR in different molecular subtypes of breast cancer and its clinical significance in the treatment and prognosis of patients with breast cancer. Methods: The plasma levels of uPA and uPAR in 86 women with primary breast cancer were determined by immunohistochemical ELISA. All patients were confirmed by histopathology and based on the results of immunohistochemistry provided by the clinicopathological data of the patients Molecular typing, combined with the two for analysis. Results: The expression of uPA in different molecular subtypes of breast cancer was statistically different (P <0.01). The expression of uPAR in different subtypes of breast cancer was statistically different (P <0.05). The levels of uPA and uPAR There was a significant positive correlation (P <0.01, Pearson correlation coefficient r = 0.735). Conclusion: The levels of plasma uPA and uPAR in patients with breast cancer are closely related to the molecular subtypes. Combined with molecular subtypes, their association with molecular subtypes may be helpful for individualized treatment and prognosis of breast cancer.